Financial Performance - The company's operating revenue for the first half of 2022 reached RMB 660,442,971.57, representing a 38.98% increase compared to RMB 475,192,916.05 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 227,587,040.03, an increase of 84.86% from RMB 123,116,314.54 in the previous year[19]. - The net cash flow from operating activities was RMB 190,763,774.39, showing a significant increase of 105.77% compared to RMB 92,706,684.08 in the same period last year[19]. - Basic earnings per share for the first half of 2022 were RMB 0.91, a 93.62% increase compared to RMB 0.47 in the same period last year[20]. - The weighted average return on equity rose to 19.56%, an increase of 7.4 percentage points from 12.16% in the previous year[21]. - The company reported a net profit excluding non-recurring gains and losses of RMB 226,278,023.88, which is an 88.20% increase from RMB 120,234,945.50 in the same period last year[19]. - The diluted earnings per share also stood at RMB 0.91, marking a 93.62% increase compared to RMB 0.47 in the previous year[21]. - Operating profit for the first half of 2022 was ¥267,659,861.76, compared to ¥144,863,414.65 in the first half of 2021, reflecting an increase of 84.8%[98]. - Net profit for the first half of 2022 was ¥227,587,040.03, up 84.9% from ¥123,116,314.54 in the first half of 2021[98]. - Total comprehensive income for the first half of 2022 was ¥246,363,622.26, compared to ¥133,565,634.28 in the first half of 2021, reflecting strong growth[101]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,625,211,546.80, a decrease of 2.72% from RMB 1,670,722,296.11 at the end of the previous year[19]. - Total liabilities decreased from ¥621,067,170.25 to ¥343,350,084.56, a decline of approximately 44.7%[91]. - The company's total assets decreased from ¥1,670,722,296.11 to ¥1,625,211,546.80, a reduction of about 2.7%[91]. - The company's retained earnings increased from ¥656,429,160.01 to ¥884,016,200.04, reflecting a growth of approximately 34.6%[91]. - The total equity increased to ¥1,384,170,913.10 from ¥1,133,201,098.34, indicating a growth of 22.1%[95]. Production Capacity and Market Position - The company has over 40,000 tons/year of production capacity for isothiazolinone industrial biocides, making it the largest producer in Asia[24]. - Sales revenue from isothiazolinone industrial biocides accounted for 99.72% of the company's total revenue, providing stable cash flow[28]. - The company has established stable long-term partnerships with major clients such as Lanxess and Oshaida, enhancing its market position[24]. - The company has a flexible production model that allows for capacity adjustments based on sales plans, ensuring timely product supply[28]. Research and Development - Research and development expenses increased by 116.12% to 31.14 million RMB, reflecting the company's commitment to innovation[34]. - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and a strong R&D team[29]. - The company plans to continue its focus on research and development in new chemical products to enhance market competitiveness[123]. Environmental Compliance and Safety - The company maintains a high standard of safety and environmental protection, complying with national and local environmental quality standards[29]. - The company reported a chemical oxygen demand (COD) discharge of 40.48 tons, which is compliant with environmental standards[58]. - The company’s nitrogen oxides emissions were recorded at 5.156 tons, also meeting the required standards[58]. - The company has completed the revision of the emergency response plan for environmental incidents in May 2022, which has been filed with the local environmental bureau[63]. - The company has established a hazardous waste disposal process that complies with relevant laws and regulations[62]. Shareholder and Stock Information - The company reported a total share count of 258,952,000 after a reduction of 2,394,400 shares, representing a decrease of approximately 0.92%[72]. - The top shareholder, Dalian Tongyun Investment Co., Ltd., held 77,106,968 shares, accounting for 29.78% of total shares, with 38,800,000 shares pledged[79]. - The company repurchased and canceled a total of 2,394,400 restricted shares due to performance assessment not meeting targets and the departure of 4 incentive plan participants, reducing total shares from 26,134,640 to 25,895,200[74]. - The company has implemented a stock incentive plan, although there have been no recent developments[54]. Financial Strategy and Cash Flow - The company incurred financial expenses of -¥9,966,883.98, a significant improvement compared to ¥554,300.05 in the previous year[100]. - The company received CNY 50,000,000.00 in borrowings during the first half of 2022, a significant decrease from CNY 398,485,572.00 in the same period of 2021, indicating a shift in financing strategy[107]. - The total cash inflow from financing activities was CNY 127,413,774.31, down from CNY 588,776,932.00 in the previous year, reflecting a decrease of 78.4%[107]. Governance and Compliance - The company received a disciplinary notice from the Shanghai Stock Exchange on May 18, 2022, involving the actual controller and financial director[68]. - There were no significant lawsuits or arbitration matters reported during the period[68]. - The financial statements were approved by the board of directors on August 15, 2022, ensuring compliance with regulatory requirements[124]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[127].

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1,006.26 million, representing a 34.25% increase compared to CNY 749.54 million in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 250.49 million, a 12.96% increase from CNY 221.75 million in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 253.48 million, up 17.98% from CNY 214.84 million in 2020[22]. - The basic earnings per share increased to CNY 1.00, a rise of 17.65% compared to CNY 0.85 in the previous year[24]. - The diluted earnings per share also rose to CNY 0.99, reflecting a 16.47% increase from the previous year[24]. - The weighted average return on equity improved to 25.12%, an increase of 4.38 percentage points from 20.74% in 2020[24]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[101]. - The company’s revenue reached 1,006.26 million yuan, a year-on-year growth of 34.25%, while the net profit attributable to shareholders was 250.49 million yuan, up 12.96%[89]. Cash Flow and Assets - The net cash flow from operating activities decreased by 32.57% to CNY 142.03 million from CNY 210.62 million in 2020[22]. - Total assets at the end of 2021 reached CNY 1,670.72 million, a 16.86% increase from CNY 1,429.70 million at the end of 2020[23]. - The company reported a significant increase in accounts receivable by 51.62% to ¥187,302,822.42 in 2021 from ¥123,535,361.89 in 2020[56]. - Inventory rose by 75.98% to ¥186,731,620.50 in 2021 from ¥106,110,749.77 in 2020, reflecting increased production capacity from the completion of the Songmu Island Phase III project[56]. - Fixed assets increased by 104.11% to ¥737,696,026.55 in 2021 from ¥361,426,530.34 in 2020, due to the completion and capitalization of the Songmu Island Phase III project[56]. Production Capacity and Operations - The company has over 40,000 tons/year of production capacity for isothiazolinone industrial biocides, solidifying its position as the largest producer in Asia[32]. - The company completed the construction of the third phase project at the Songmu Island subsidiary, which began trial production in September 2021[32]. - The production of CIT/MIT series products has a capacity of 12,000 tons, while MIT series products have a capacity of 2,000 tons[37]. - The company achieved an industrial biocide output of 41,208.71 tons, representing a year-on-year increase of 16.51%, with a capacity utilization rate of 101.56%[89]. - The completion of the third phase project at Songmu Island has added production capacity of 12,000 tons/year for CIT/MIT, 2,000 tons/year for MIT, 1,200 tons/year for OIT, and 2,500 tons/year for BIT, bringing the total industrial biocide capacity to 40,000 tons/year[73]. Research and Development - The company invested 40,031,669.69 RMB in R&D, reflecting a 40.12% increase from the previous year[41]. - Research and development expenditures over the past three years were 28.14 million yuan, 28.57 million yuan, and 40.03 million yuan, accounting for 3.23%, 3.81%, and 3.98% of operating income respectively, indicating a steady increase in both absolute and relative terms[87]. - The company has developed over 50 formula products, with more than 30 currently on sale, which have higher sales prices and gross profit margins compared to raw materials[88]. Market and Sales - Approximately 50% of the company's revenue comes from international clients, with major clients including global chemical giants such as Lanxess and Oshada[88]. - The company plans to continue seeking international partnerships to enhance brand recognition and expand its market share globally[88]. - The sales model is primarily direct sales, targeting technical service providers and industrial biocide traders[36]. Governance and Compliance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring good investor relations and effective information disclosure[95]. - The company has maintained a focus on enhancing its internal control systems to improve governance quality[95]. - The company has not reported any significant changes in the competitive landscape or measures taken to address potential conflicts of interest with controlling shareholders[95]. - The company has not disclosed any significant related party transactions during the reporting period, indicating a focus on transparency[167]. Environmental Responsibility - The company reported a chemical oxygen demand (COD) wastewater discharge of 54 tons from its Songmu Island subsidiary, which met the environmental standards[136]. - The company’s Lushun subsidiary reported a COD wastewater discharge of 3.998 tons, also in compliance with environmental standards[138]. - The company has installed automatic monitoring facilities for pollutants at discharge points, with all monitored pollutants meeting discharge standards[144]. - The company has completed the environmental impact assessments for construction projects and has not faced penalties from regulatory authorities[145]. Risks and Challenges - The company faces risks related to environmental protection, safety production, raw material price fluctuations, and exchange rate volatility, which could impact operational performance[91][92]. - The company has acknowledged the existence of non-operating fund occupation by controlling shareholders and their affiliates[8]. - The company has reported a significant increase in freight costs, which rose by 98.95% year-on-year to approximately ¥51.65 million, indicating higher logistics expenses[47]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year, targeting 1.65 billion[101]. - The company anticipates continued growth in the domestic application market for isothiazolinone biocides, despite challenges from raw material price fluctuations and global pandemic impacts[85].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 294,068,308.89, representing a year-on-year increase of 34.65%[2] - The net profit attributable to shareholders was CNY 98,465,601.61, reflecting an increase of 89.97% compared to the same period last year[2] - Basic earnings per share were CNY 0.39, marking a 95.00% increase from the previous year[2] - The net profit after deducting non-recurring gains and losses was CNY 97,622,683.95, up 92.41% year-on-year[2] - The net profit for Q1 2022 was CNY 98,465,601.61, representing a 90% increase compared to CNY 51,831,316.56 in Q1 2021[18] - Operating profit for Q1 2022 reached CNY 117,161,373.68, up from CNY 61,054,786.14 in the same period last year, indicating a growth of approximately 92%[18] - The total comprehensive income for Q1 2022 was CNY 98,464,327.84, compared to CNY 51,831,316.56 in Q1 2021, indicating a substantial increase[19] Cash Flow - The net cash flow from operating activities reached CNY 115,713,254.47, up by 146.95% year-on-year[2] - Cash flow from operating activities for Q1 2022 was CNY 115,935,294.28, significantly higher than CNY 57,526,819.63 in Q1 2021, indicating a 101% increase[30] - The company reported a cash and cash equivalents balance of CNY 174,333,494.91 at the end of Q1 2022, compared to CNY 165,194,669.93 at the end of Q1 2021[23] - The cash and cash equivalents decreased by $36,487,878.77 during the period, compared to a decrease of $14,104,752.16 in the prior period[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,843,367,714.24, a 10.33% increase from the end of the previous year[3] - Total assets reached RMB 1,843,367,714.24 as of March 31, 2022, compared to RMB 1,670,722,296.11 at the end of 2021, marking a growth of 10.3%[14] - Total liabilities as of March 31, 2022, were RMB 692,945,164.29, up from RMB 621,067,170.25 at the end of 2021, reflecting an increase of 11.6%[13] - The company's total liabilities decreased to CNY 529,547,694.94 in Q1 2022 from CNY 551,951,327.46 in Q1 2021, a reduction of about 4%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,026[6] - Major shareholder Dalian Tongyun Investment Co., Ltd. held 29.50% of the shares, with 38,800,000 shares pledged[7] Research and Development - Research and development expenses in Q1 2022 amounted to RMB 14,891,195.96, significantly higher than RMB 6,142,918.54 in Q1 2021, indicating a 142.5% increase[17] - Research and development expenses increased significantly to CNY 14,390,713.41, up from CNY 5,612,029.90 in the previous year, marking a 156% rise[28] Operating Costs - Total operating costs for Q1 2022 were RMB 178,026,084.85, up from RMB 151,813,050.45 in Q1 2021, reflecting a year-over-year increase of 17.4%[17] - The company's operating expenses, including sales and management costs, totaled CNY 39,073,204.35 in Q1 2022, compared to CNY 20,756,356.47 in Q1 2021, reflecting an increase of 88%[28] Financial Position - The weighted average return on equity increased by 3.69 percentage points to 8.96%[2] - The total equity of the company as of Q1 2022 was CNY 1,241,084,742.59, compared to CNY 1,133,201,098.34 in Q1 2021, showing an increase of approximately 10%[26] Investment Activities - Investment activities resulted in a net cash outflow of CNY 86,736,221.83 in Q1 2022, compared to a net outflow of CNY 77,700,663.70 in Q1 2021[22] - The cash outflow related to investment activities was $87,365,672.82, compared to $99,325,373.33 in the previous period[31]

Financial Performance - The company's operating revenue for Q3 2021 was CNY 216,757,283.85, representing a year-on-year increase of 28.14%[5] - The net profit attributable to shareholders for Q3 2021 was CNY 37,016,596.19, a decrease of 27.20% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,060,722.47, down 27.78% year-on-year[5] - The basic earnings per share for Q3 2021 was CNY 0.14, a decrease of 26.32% compared to the previous year[6] - The company achieved a revenue of CNY 691,950,199.90 for the year-to-date period, with a growth of 22.07% compared to the previous year[5] - Net profit for the first three quarters of 2021 was ¥160,132,910.73, compared to ¥178,809,189.22 in the same period of 2020, reflecting a decrease of approximately 10.5%[19] - The net profit attributable to the parent company for Q3 2021 was ¥160,132,910.73, a decrease of 10.5% compared to ¥178,809,189.22 in Q3 2020[20] - The total comprehensive income for Q3 2021 was ¥160,129,604.32, down from ¥178,818,813.85 in Q3 2020, indicating a decline of 10.5%[20] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was CNY 110,730,001.27, showing a decline of 37.70%[6] - Cash flow from operating activities for the first nine months of 2021 was ¥110,730,001.27, a decrease of 37.7% compared to ¥177,745,793.52 in the same period of 2020[24] - The company's cash and cash equivalents decreased to ¥259,973,709.50 from ¥333,068,462.74, a decline of about 22.0%[15] - The cash and cash equivalents at the end of Q3 2021 were ¥171,751,306.49, a decrease from ¥340,900,855.18 at the end of Q3 2020[25] - The company's total assets as of September 30, 2021, amounted to ¥1,575,314,359.12, an increase from ¥1,429,695,956.74 at the end of 2020, showing a growth of about 10.2%[16] Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥504,962,989.47, up from ¥365,746,716.33 in 2020, indicating an increase of about 38.1%[18] - The company reported a financial expense of ¥4,875,748.81 for the first three quarters of 2021, compared to ¥3,276,229.29 in 2020, representing an increase of about 48.8%[19] - Research and development expenses for the first three quarters of 2021 were ¥24,939,361.32, up from ¥19,438,181.25 in 2020, indicating an increase of approximately 28.6%[19] Equity and Liabilities - Current liabilities totaled ¥571,927,752.96 as of September 30, 2021, compared to ¥396,049,476.04 at the end of 2020, representing an increase of approximately 44.2%[16] - The total equity attributable to shareholders decreased to ¥961,270,047.38 from ¥988,283,192.35, a decline of approximately 2.7%[16] Business Strategy - The company plans to adjust product prices in response to fluctuations in raw material costs to alleviate cost pressures[12] - The industrial biocide business continues to show stable growth, although profit growth has slowed due to rising raw material prices[12] Cash Flow from Activities - Total cash inflow from investing activities was ¥10,365,250.00, while cash outflow was ¥173,777,347.45, resulting in a net cash outflow of ¥163,412,097.45 for the first nine months of 2021[25] - Cash inflow from financing activities for the first nine months of 2021 was ¥640,271,307.00, significantly higher than ¥330,000,000.00 in the same period last year, marking an increase of 94.5%[25] - The net cash flow from financing activities was ¥45,211,675.42, compared to a minimal increase of ¥353,425.32 in the same period of 2020[25] Other Comprehensive Income - The company received ¥23,159,625.54 in tax refunds related to operating activities, an increase from ¥10,184,577.94 in the same period last year[24] - The company reported a decrease in other comprehensive income after tax, with a net amount of -¥3,306.41 for Q3 2021 compared to ¥9,624.63 in Q3 2020[20]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately RMB 475.19 million, representing a 19.48% increase compared to RMB 397.70 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was approximately RMB 123.12 million, a decrease of 3.79% from RMB 127.96 million in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 120.23 million, down 4.70% from RMB 126.17 million in the same period last year[19]. - The net cash flow from operating activities for the first half of 2021 was approximately RMB 92.71 million, a decrease of 3.93% compared to RMB 96.50 million in the previous year[19]. - The total assets at the end of the reporting period were approximately RMB 1.49 billion, an increase of 4.04% from RMB 1.43 billion at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately RMB 920.01 million, a decrease of 6.91% from RMB 988.28 million at the end of the previous year[19]. - The basic earnings per share for the first half of 2021 were RMB 0.47, down 4.08% from RMB 0.49 in the same period last year[17]. - The weighted average return on net assets for the first half of 2021 was 12.16%, an increase of 0.09 percentage points compared to 12.07% in the previous year[17]. - The gross profit margin for the industrial biocide business remained high at 45.63%[36]. Cash Flow and Investments - The company’s cash flow from operating activities decreased by 3.93% to CNY 92.71 million[39]. - The company plans to invest CNY 483 million in the Songmu Island Phase III project, with CNY 251.83 million already invested as of June 2021[46]. - The company reported a total cash inflow from financing activities of approximately ¥588.78 million, significantly higher than ¥330.00 million in the same period of 2020[117]. - The total cash outflow from financing activities was ¥594,739,537.19, compared to ¥299,538,567.27, an increase of 98.7%[120]. - The company received ¥398,485,572.00 in borrowings, a substantial increase from ¥30,000,000.00 in the previous period[120]. Market Position and Operations - The company's sales revenue from isothiazolinone industrial biocide raw materials accounted for 98.22% of total consolidated revenue, providing stable cash flow and directly impacting overall profitability and performance[28]. - The total production capacity of the company exceeds 30,000 tons, making it the largest producer of isothiazolinone industrial biocide raw materials in Asia, with plans to exceed 40,000 tons by the end of 2021[29]. - The company has established stable long-term partnerships with major clients such as Dow Chemical and Lanxess, enhancing its competitive advantage in the market[22]. - The company employs a direct sales model, primarily targeting industrial biocide solution providers and traders, ensuring efficient market reach[25]. - The company has established a strong market position with a high market share, benefiting from nearly 20 years of experience in the isothiazolinone industrial biocide market[33]. Research and Development - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and continuously improving its R&D capabilities[31]. - The company’s R&D expenses increased by 35.74% to CNY 14.41 million, reflecting ongoing innovation efforts[39]. - Research and development expenses for the first half of 2021 were ¥14,409,271.65, compared to ¥10,615,482.28 in the same period last year, representing a 35.5% increase[109]. Environmental and Safety Compliance - The company maintains a strong focus on safety and environmental protection, ensuring compliance with national and local environmental standards[32]. - The company emphasized the importance of environmental protection, facing increased costs due to stricter regulations, which may impact profitability[48]. - Safety production risks are highlighted due to the use of hazardous chemicals, with ongoing efforts to enhance safety training and internal controls[49]. - The company has invested in high-standard environmental protection facilities and personnel to comply with regulations[48]. - The company reported a total of 27.6 tons of chemical oxygen demand (COD) discharged, which is compliant with environmental standards[63]. Shareholder and Governance - A new board of directors and senior management team was elected in April 2021, indicating a leadership change[56]. - The company has committed to respecting the control position of Dalian Baiao Chemical Co., Ltd. by its major shareholder, Sanxin Investment, which will hold shares as a financial investor without seeking control of the company[76]. - The company plans to grant a total of 5.82 million restricted stocks to 64 incentive objects, with an initial grant of 5.52 million shares and a reserved 300,000 shares, at a price of 7.36 CNY per share[59]. - The company has not reported any major litigation or arbitration matters during the reporting period[79]. - The total number of shares after the recent changes is 261,346,400, with 5,461,000 shares being reduced from the unrestricted circulating shares[83]. Risks and Challenges - The report includes a risk statement indicating that future plans and industry trends do not constitute a commitment to investors, highlighting the importance of investment risk awareness[3]. - The company faces industry policy risks related to environmental and safety regulations, which could affect continuous production[50]. - Currency fluctuation risks are significant as international sales constitute a large portion of total revenue, primarily settled in USD[51]. Financial Reporting and Accounting Policies - The company’s financial statements were approved by the board of directors on August 24, 2021[132]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[136]. - The company’s accounting policies are tailored to its operational characteristics, particularly in areas such as accounts receivable and inventory valuation[137]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[146].

Financial Performance - Operating revenue for the first quarter reached CNY 218,397,085.71, a year-on-year increase of 9.37%[7] - Net profit attributable to shareholders decreased by 42.38% to CNY 51,831,316.56 compared to the same period last year[7] - Basic earnings per share fell by 41.18% to CNY 0.20[7] - The weighted average return on equity decreased by 3.11 percentage points to 5.27%[7] - Total operating revenue for Q1 2021 was CNY 218,397,085.71, an increase of 9.6% compared to CNY 199,682,629.30 in Q1 2020[30] - Gross profit for Q1 2021 was CNY 66,584,035.26, compared to CNY 99,569,350.15 in Q1 2020, indicating a decrease in profitability[30] - The net profit for Q1 2021 was CNY 51,831,316.56, representing a decrease of 42.4% from CNY 89,960,059.62 in Q1 2020[32] - The total profit for Q1 2021 was CNY 61,053,791.33, down from CNY 99,771,299.37 in Q1 2020, indicating a decline of 38.8%[31] Assets and Liabilities - Total assets increased by 6.32% to CNY 1,520,021,841.48 compared to the end of the previous year[7] - Total assets as of March 31, 2021, amounted to CNY 1,525,056,004.36, an increase from CNY 1,428,631,511.24 at the end of 2020[27] - Current liabilities totaled ¥480,516,093.42, an increase from ¥396,049,476.04 at the beginning of the period[22] - Total liabilities as of March 31, 2021, were CNY 478,988,620.94, compared to CNY 396,056,440.26 at the end of 2020, indicating increased leverage[27] - Total liabilities amounted to CNY 441,412,764.39, with non-current liabilities totaling CNY 45,363,288.35[43] - Owner's equity stood at CNY 988,283,192.35, with retained earnings of CNY 574,691,374.21[43] Cash Flow - Net cash flow from operating activities decreased by 41.40% to CNY 46,857,098.90[7] - The net cash flow from operating activities for Q1 2021 was CNY 46,857,098.90, a decrease of 41.5% from CNY 79,967,742.71 in Q1 2020[36] - The company experienced a net cash outflow from investing activities of ¥88,964,063.33 in Q1 2021, compared to a net outflow of ¥29,978,644.00 in Q1 2020, indicating a significant increase in investment expenditures[39] - Cash inflow from financing activities was ¥61,873,792.00 in Q1 2021, with a net cash flow from financing activities of ¥16,595,711.30, contrasting with a net outflow of ¥396,700.00 in Q1 2020[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,293[13] - The top two shareholders, Dalian Tongyun Investment Co., Ltd. and Dalian Sanxin Investment Co., Ltd., hold 29.00% and 28.00% of shares respectively[13] Research and Development - Research and development expenses surged by 287.55% to ¥6,142,918.54, reflecting significant expenditures on process improvements[16] - Research and development expenses for Q1 2021 were CNY 6,142,918.54, significantly higher than CNY 1,585,064.72 in Q1 2020, reflecting a focus on innovation[30] Operational Costs - Operating costs rose by 62.03% to ¥119,283,001.94, driven by rising raw material prices and the reclassification of certain expenses under new revenue recognition standards[16] - Total operating costs for Q1 2021 were CNY 151,813,050.45, up from CNY 100,113,279.15 in Q1 2020, representing a 51.5% increase[30] Inventory and Asset Management - Inventory levels decreased to CNY 73,251,196.52 from CNY 91,459,227.13 at the end of 2020, indicating improved inventory management[26] - The company reported a significant asset impairment loss of 21,485.33% due to a decline in product prices, resulting in inventory write-downs[16] Other Financial Metrics - Non-recurring gains and losses totaled CNY 1,095,802.21 for the period[10] - The company's trading financial assets decreased by 100% to 0 due to the maturity of structured deposits[15] - Accounts receivable financing decreased by 39.89% to ¥6,412,665.12, attributed to a reduction in receivable notes[15]

Financial Performance - The company's operating revenue for 2020 was CNY 749,541,031.81, a decrease of 14.03% compared to CNY 871,896,072.63 in 2019[20] - The net profit attributable to shareholders for 2020 was CNY 221,754,543.29, down 27.72% from CNY 306,801,352.58 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 214,843,244.43, a decrease of 27.81% compared to CNY 297,626,223.40 in 2019[20] - Basic earnings per share decreased by 27.35% to CNY 0.85 in 2020 from CNY 1.17 in 2019[21] - Weighted average return on equity fell by 12.76 percentage points to 20.74% in 2020 from 33.50% in 2019[21] - The company reported a net profit margin of approximately 35.0% for 2020, down from 41.0% in 2019, indicating a decrease in profitability[183] - The total comprehensive income for 2020 was CNY 221,713,080.63, down from CNY 306,929,021.88 in 2019, indicating a decline of 27.77%[185] Cash Flow and Assets - The net cash flow from operating activities for 2020 was CNY 210,615,284.82, down 12.27% from CNY 240,066,206.82 in 2019[20] - The company's cash and cash equivalents increased to CNY 333,068,462.74, compared to CNY 242,123,892.62 in the previous year, marking a growth of approximately 37.6%[176] - Total liabilities rose to CNY 396,056,440.26 in 2020 from CNY 108,250,973.30 in 2019, a significant increase of 266.5%[182] - The company's equity decreased to CNY 1,032,575,070.98 in 2020 from CNY 1,089,165,801.99 in 2019, a decline of 5.2%[182] - The total assets increased to CNY 1,428,631,511.24 in 2020 from CNY 1,197,416,775.29 in 2019, an increase of 19.3%[182] Revenue Breakdown - The company's domestic sales accounted for approximately 53% of total revenue, while international sales made up about 47%, with key markets in Europe, Asia, and North America[31] - The company’s international revenue accounts for nearly half of its total income, primarily from major clients like Dow Chemical and Lanxess[83] - The company reported a total non-current asset value of RMB 818,180,539.83, up from RMB 667,500,104.59 in 2019, indicating a growth of approximately 22.6%[177] Production and Capacity - The company has an annual production capacity of over 30,000 tons of isothiazolinone industrial biocides, with plans to expand capacity to over 40,000 tons by the end of 2021 due to ongoing construction of the Songmu Island Phase III project[41] - The production volume of industrial biocides reached 35,369.77 tons, representing a year-on-year increase of 12.03%, with a capacity utilization rate of 96%[85] - The company has established long-term stable partnerships with major international clients such as Dow Chemical, Lonza, and Lanxess, enhancing its market position[33] Research and Development - Research and development expenses increased by 1.53% to ¥28,569,156.99, accounting for 3.81% of total revenue[55] - The company has 16 invention patents and 8 utility model patents, reflecting its strong R&D capabilities and commitment to technological innovation[36] - Research and development investments over the past three years were 19.15 million RMB, 28.14 million RMB, and 28.57 million RMB, accounting for 3.63%, 3.23%, and 3.81% of revenue respectively, indicating a steady increase[82] Environmental and Safety Compliance - The company has faced environmental protection risks due to its classification as a heavily polluting industry, leading to increased environmental spending and costs[86] - The company has committed to strict adherence to environmental and safety regulations, which may impact continuous production due to potential shutdowns during inspections[86] - The company operates 22 sets of exhaust gas treatment devices, utilizing multi-stage condensation and absorption technology to prevent uncontrolled gas emissions[109] Shareholder Information - The top shareholder, Dalian Tongyun Investment Co., Ltd., holds 75,786,668 shares, representing 29.00% of the total shares[128] - The total number of ordinary shareholders increased to 15,716 by the end of the reporting period[126] - The company has undergone a change in controlling shareholders, with Dalian Tongyun Investment becoming the primary shareholder as of February 7, 2020[131] Management and Governance - The total pre-tax compensation for the board members and senior management during the reporting period amounted to 6.7054 million CNY[144] - The management team has extensive experience in various sectors, including finance, chemical engineering, and corporate management[146] - The company confirmed that there were no significant differences in corporate governance compared to the requirements set by the China Securities Regulatory Commission[161]

2020 年第三季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2020 年第三季度报告 1 / 28 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 10 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人刘宪武、主管会计工作负责人王希梁及会计机构负责人（会计主管人员）肖红红 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 28 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增减 (%) 总资产 1,499,263,652.52 1,189,296,891.60 26.06 归属于上市公司 股东的净资产 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 397.70 million, representing a 13.67% increase compared to CNY 349.89 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2020 was CNY 127.96 million, up 13.69% from CNY 112.56 million in the previous year[18]. - The net cash flow from operating activities was CNY 96.50 million, reflecting a 16.27% increase from CNY 82.99 million in the same period last year[18]. - The basic earnings per share for the first half of 2020 was CNY 0.49, an increase of 13.95% compared to CNY 0.43 in the same period last year[20]. - The diluted earnings per share also stood at CNY 0.49, marking a 13.95% increase year-on-year[20]. - The company reported a net profit after deducting non-recurring gains and losses of CNY 126.17 million, which is a 16.20% increase from CNY 108.58 million in the same period last year[18]. - The company's main business saw a revenue of CNY 397.60 million, with a net profit of CNY 121.77 million, marking increases of 15.26% and 10.31% respectively[43]. - The company reported a total comprehensive income of CNY 121,767,091.93 for the first half of 2020, reflecting a significant recovery compared to the previous period[127]. Cash Flow and Assets - The total assets at the end of the reporting period amounted to CNY 1,049,433,564.59, reflecting a stable financial position[122]. - The company's total liabilities increased to CNY 432,846,282.14 as of June 30, 2020, compared to CNY 155,828,392.22 at the end of 2019, marking a significant rise of about 177.5%[98]. - The company's current assets totaled CNY 521,796,787.01 as of June 30, 2020, down from CNY 799,885,203.58 at the end of 2019, indicating a decrease of about 34.8%[96]. - The total cash and cash equivalents at the end of the period amounted to CNY 328,210,197.40, compared to CNY 145,504,299.13 at the end of the first half of 2019, indicating a significant increase of 125.0%[113]. - The company reported a total of CNY 501,928,637.17 in undistributed profits as of June 30, 2020, compared to CNY 485,973,196.59 at the end of 2019, indicating an increase of approximately 3.5%[98]. Research and Development - Research and development expenses increased by 38.30% to CNY 10.62 million, reflecting the company's commitment to innovation[46]. - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and maintaining a strong R&D team[36]. Market Position and Operations - The main business remains focused on the research, production, and sales of fine chemical products, specifically isothiazolinone-based industrial biocides and the intermediate chemical 2-chlorobenzonitrile (F-nitrile)[25]. - The total production capacity for isothiazolinone-based industrial biocides exceeds 30,000 tons, positioning the company as the largest producer in Asia[34]. - The company has established stable long-term partnerships with major clients such as Dow Chemical and Lanxess, enhancing its market position[32]. - The company’s product range includes CIT/MIT, MIT, OIT, DCOIT, and BIT series, catering to diverse customer needs across various industries[35]. - The company’s sales model is primarily direct sales, targeting industrial biocide solution providers and traders[29]. Environmental Compliance and Safety - The company emphasized its commitment to environmental protection, investing in high-standard facilities and adhering to strict regulations, which may impact profitability[58]. - The company has established a quality management system in accordance with ISO9001 standards, enhancing product quality and market competitiveness[39]. - The company has a wastewater treatment facility with a capacity of 100 tons per day, which processes both production and domestic wastewater, meeting discharge standards[73]. - The company operates a biochemical wastewater treatment facility at Songmu Island with a construction scale of 960 tons per day, currently running at 800 tons per day, achieving compliant discharge[72]. - The company conducts regular third-party monitoring of wastewater and exhaust emissions, ensuring compliance with environmental standards[76]. Shareholder and Capital Structure - The total number of shares increased from 186,676,000 to 261,346,400, with the proportion of listed circulating shares rising to 100%[80]. - The company’s major shareholders have undergone changes, with Dalian Tongyun Investment Co., Ltd. becoming the new controlling shareholder as of February 8, 2020[89]. - The top two shareholders, Dalian Tongyun Investment Co., Ltd. and Dalian Sanxin Investment Co., Ltd., held 29.00% and 28.84% of shares respectively, with significant portions pledged[87]. - The company reported a net asset value per share at 4.02 yuan, up from 3.95 yuan at the end of the previous year, marking a 1.77% increase[82]. Strategic Initiatives - The company is investing CNY 483 million in the third phase of the industrial biocide project, with a construction period of 24 months, expected to commence production in early 2022[44]. - The company faced challenges in export business due to ongoing pandemic conditions in Europe and the US, affecting demand for biocides[43]. - The company faced a decline in market demand due to the COVID-19 pandemic, leading to a strategic shift towards domestic market development to mitigate risks[56]. Financial Liabilities and Investments - The company’s total liabilities at the end of the reporting period were CNY 501,928,637.17, indicating a manageable debt level relative to its equity[122]. - The company has entered into agreements to replace original financial liabilities with new financial liabilities, recognizing the difference between the book value and the consideration paid as current profit or loss[167]. - The company recognizes expected credit losses based on the risk of default, with losses recognized for financial assets measured at amortized cost and those measured at fair value through other comprehensive income[171].

2020 年第一季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2020 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2020 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 1,303,153,051.92 | 1,189,296,891.60 | | 9.57 | | 归属于上市公司 | 1,139,114,008.03 | 1,033,468,499.38 | | 10.22 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | 79,967,742.71 | 27,358,318.20 | | 192.30 | | 现金流量净额 ...